Literature DB >> 2976808

Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases.

P Dostert1, M Strolin Benedetti, G Dordain.   

Abstract

Tetrahydroisoquinoline (TIQ) alkaloids and 1-carboxy TIQ derivatives have been found in human fluids and/or tissues. The possible biosynthetic pathways of salsolinol (Sal), taken as an example of TIQs, are discussed, and the possibility that biosynthesis occurs through a stereospecific enzymatic reaction is considered. In this respect, it is reported that the R enantiomer of Sal predominates in urines of healthy volunteers, whereas the S enantiomer predominates in port wine and possibly in other beverages and foods, suggesting that Sal present in humans could have, at least partially, and endogenous enzymatic origin. TIQs and other dopamine-derived alkaloids are weak MAO inhibitors, the R enantiomer of Sal and salsolidine being more potent than the S form. The changes in monoamine oxidase activity and the nigrostriatal concentrations of dopamine and homovanillic acid in Parkinson's and Huntington's diseases and in alcoholism are reviewed. In these pathological situations, changes in the levels of dopamine-derived alkaloid levels may occur. The possibility that the modifications found might cause or contribute to changes in mental and/or neurophysiological states in these pathological situations is considered.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2976808     DOI: 10.1007/bf01245140

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  50 in total

1.  Effects of L-dopa metabolites at a dopamine receptor suggest a basis for 'on-off' effect in Parkinson's disease.

Authors:  D Dougan; D Wade; P Mearrick
Journal:  Nature       Date:  1975-03-06       Impact factor: 49.962

2.  Augmentation of alkaloid formation from dopamine by alcohol and acetaldehyde in vitro.

Authors:  V E Davis; M J Walsh; Y Yamanaka
Journal:  J Pharmacol Exp Ther       Date:  1970-09       Impact factor: 4.030

3.  Dementia in Parkinson's disease and (pre) senile dementia of Alzheimer type: morphological aspects and changes in the intracerebral MAO activity.

Authors:  K Jellinger; P Riederer
Journal:  Adv Neurol       Date:  1984

4.  Ethanol preference in rats: increased consumption after intraventricular administration of tetrahydropapaveroline.

Authors:  A Clow; I P Stolerman; R M Murray; M Sandler
Journal:  Neuropharmacology       Date:  1983-04       Impact factor: 5.250

5.  Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia.

Authors:  E D Bird; L L Iversen
Journal:  Brain       Date:  1974-09       Impact factor: 13.501

6.  Rat brain salsolinol and blood-brain barrier.

Authors:  T Origitano; J Hannigan; M A Collins
Journal:  Brain Res       Date:  1981-11-16       Impact factor: 3.252

7.  Possible new metabolites mediating actions of L-dopa.

Authors:  T L Sourkes
Journal:  Nature       Date:  1971-02-05       Impact factor: 49.962

8.  In vivo and in vitro studies on the effect of tetrahydropapaveroline and salsolinol on COMT and MAO activity in rat brain.

Authors:  A Giovine; M Renis; A Bertolino
Journal:  Pharmacology       Date:  1976       Impact factor: 2.547

9.  Dopamine-related tetrahydroisoquinolines: significant urinary excretion by alcoholics after alcohol consumption.

Authors:  M A Collins; W P Nijm; G F Borge; G Teas; C Goldfarb
Journal:  Science       Date:  1979-12-07       Impact factor: 47.728

10.  Alcohol drinking: abnormal intake caused by tetrahydropapaveroline in brain.

Authors:  R D Myers; C L Melchior
Journal:  Science       Date:  1977-04-29       Impact factor: 47.728

View more
  12 in total

1.  Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease.

Authors:  Zakiya Qualls; Dwayne Brown; Carlana Ramlochansingh; Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-01       Impact factor: 3.911

2.  Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

Authors:  A Moser; F Siebecker; P Vieregge; P Jaskowski; D Kömpf
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 3.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects.

Authors:  P Dostert; M S Benedetti; V Bellotti; C Allievi; G Dordain
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 5.  Not Just from Ethanol. Tetrahydroisoquinolinic (TIQ) Derivatives: from Neurotoxicity to Neuroprotection.

Authors:  Alessandra T Peana; Valentina Bassareo; Elio Acquas
Journal:  Neurotox Res       Date:  2019-05-02       Impact factor: 3.911

6.  Effect of aging on dopamine metabolism in the rat cerebral cortex: a regional analysis.

Authors:  F Godefroy; M H Bassant; Y Lamour; J Weil-Fugazza
Journal:  J Neural Transm Gen Sect       Date:  1991

7.  Urinary elimination of salsolinol enantiomers in alcoholics.

Authors:  P Dostert; M Strolin Benedetti; G Dordain; D Vernay
Journal:  J Neural Transm Gen Sect       Date:  1991

8.  Influence of food intake on the enantiomeric composition of urinary salsolinol in man.

Authors:  M Strolin Benedetti; P Dostert; P Carminati
Journal:  J Neural Transm Gen Sect       Date:  1989

9.  Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system.

Authors:  T Takahashi; Y Deng; W Maruyama; P Dostert; M Kawai; M Naoi
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Ratio of the R and S enantiomers of salsolinol in food and human urine.

Authors:  M Strolin Benedetti; V Bellotti; E Pianezzola; E Moro; P Carminati; P Dostert
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.